Gilder Gagnon Howe & CO LLC Arcus Biosciences, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

$7.87 Billion
Q3 2024

A detailed history of Gilder Gagnon Howe & CO LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 126,386 shares of RCUS stock, worth $1.88 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

126,386

Previous 138,027 8.43%

Holding current value

$1.88 Million

Previous $2.1 Million 8.09%

% of portfolio

0.02%

Previous 0.03%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $159,365 - $209,654	-11,641 Reduced 8.43%	126,386 $1.93 Million
Q2 2024 Aug 14, 2024	SELL	$14.59 - $18.48 $534,402 - $676,885	-36,628 Reduced 20.97%	138,027 $2.1 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $526,242 - $716,087	35,485 Added 25.5%	174,655 $3.3 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $1.33 Million - $1.95 Million	-99,362 Reduced 41.66%	139,170 $2.66 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $46,816 - $62,545	-2,657 Reduced 1.1%	238,532 $4.28 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $221,933 - $288,108	13,078 Added 5.73%	241,189 $4.9 Million
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $171,218 - $248,353	-10,728 Reduced 4.49%	228,111 $4.16 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $47,043 - $85,275	-2,388 Reduced 0.99%	238,839 $4.94 Million
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $444,738 - $575,690	19,145 Added 8.62%	241,227 $6.31 Million
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $1.19 Million - $2.61 Million	-69,198 Reduced 23.76%	222,082 $5.63 Million
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $40,140 - $58,060	-1,388 Reduced 0.47%	291,280 $9.19 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $52,247 - $80,702	1,665 Added 0.57%	292,668 $11.8 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $163,869 - $229,282	-6,085 Reduced 2.05%	291,003 $10.1 Million
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $162,071 - $254,825	-7,124 Reduced 2.34%	297,088 $8.16 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $303,429 - $480,082	-11,599 Reduced 3.67%	304,212 $8.54 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $9.43 Million - $18 Million	-554,823 Reduced 63.73%	315,811 $8.2 Million
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $1.12 Million - $1.67 Million	65,560 Added 8.14%	870,634 $14.9 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $11 Million - $28.7 Million	784,944 Added 3899.37%	805,074 $19.9 Million
Q1 2020 May 15, 2020	SELL	$8.78 - $19.28 $10,764 - $23,637	-1,226 Reduced 5.74%	20,130 $279,000
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $3,232 - $4,758	441 Added 2.11%	21,356 $216,000
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $3,039 - $4,804	472 Added 2.31%	20,915 $190,000
Q2 2019 Aug 13, 2019	BUY	$7.29 - $13.38 $149,029 - $273,527	20,443 New	20,443 $163,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.08B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.

Account

Gilder Gagnon Howe & CO LLC Arcus Biosciences, Inc. Transaction History